Bill Anderson
Chairman of the Board of Management and Chief Executive OfficerBayer
PharmaceuticalsView Profile →Executive Chairman · Vertex Pharmaceuticals
Jeffrey Leiden is executive chairman of Vertex Pharmaceuticals and its former CEO. A physician and scientist, he has worked in academic medicine, pharmaceutical management and life-sciences venture capital.
Last reviewed: Nov 2, 2026
Executive Chairman
Vertex Pharmaceuticals
Last Reviewed: November 2, 2026
Jeffrey Leiden is executive chairman of Vertex Pharmaceuticals and its former CEO. A physician and scientist, he has worked in academic medicine, pharmaceutical management and life-sciences venture capital.
Leiden began his career in academic medicine as a cardiologist and molecular biologist. His appointments included chief of cardiology and director of the Cardiovascular Research Institute at the University of Chicago, followed by professorships at Harvard Medical School and the Harvard School of Public Health. He also participated in starting biotechnology companies, including Vical and Cardiogene.
He joined Abbott Laboratories in 2000 and became president and chief operating officer of its Pharmaceutical Products Group in December 2001. His responsibilities also included chief scientific officer and board service. During his Abbott tenure, he worked on development and commercialization of medicines including Humira and Kaletra.
Leiden moved to Clarus Ventures as a managing director in 2006. He joined Vertex’s board in July 2009, served as lead independent director and became president and CEO in February 2012. He added the chairmanship that May.
During his CEO tenure, Vertex developed and commercialized cystic-fibrosis medicines including Kalydeco, Orkambi and Trikafta. Leiden established the 2015 collaboration with CRISPR Therapeutics and led the 2019 acquisition of Semma Therapeutics, extending the company’s work into gene editing and cell-based diabetes therapies. He also established a STEAM education program involving learning laboratories, mentorship and scholarships.
He became executive chairman in April 2020. His outside commitments include lead independent director of MassMutual, chairmanships of Odyssey Therapeutics and Casana, and service on the MIT CEO Advisory Board. He is an elected member of the National Academy of Medicine.
Leiden earned a Bachelor of Arts in biological sciences, a PhD in virology and a medical degree from the University of Chicago.